First Canadian Blood Center to Implement Revolutionary Technology
LAKEWOOD, Colo.—April 21, 2008— CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies announced today that Héma-Québec, the only blood products provider in Québec, has entered into a multi-year agreement to purchase Atreus® Whole Blood Processing and Orbisac® Systems to simplify and automate the process of producing whole blood components.
‘’By implementing this new technology from CaridianBCT, we intend to optimize our operations procedures and fulfill our mission to efficiently provide adequate quantities of safe, optimal blood components to meet the needs of Québec residents,’’ said Dr Francine Décary, president and chief executive officer of Héma-Québec.
The Atreus system simplifies whole blood manufacturing with automation and informatics—enabling blood centers to produce high quality blood components, enhance scalability and flexibility, and improve operational performance. The OrbiSac device allows the processing of buffy coat platelets produced from the Atreus system into a single pooled platelet product ready for transfusion. The synergy between Atreus and OrbiSac systems has demonstrated increased product quality consistency, increased component lab staff satisfaction and productivity.
“We are excited to continue our long-standing relationship with Héma-Québec as they become the first blood center in Canada to adopt our innovative approach to whole blood manufacturing,” said David B. Perez, president and chief executive officer of CaridianBCT. “At CaridianBCT, we are dedicated to providing blood centers with technology that brings efficiency and automation in whole blood processing to ultimately benefit patients with the life saving gift of blood.
About Atreus Whole Blood Processing and Orbisac systems:
The Atreus Whole Blood Processing system received the CE Mark in 2006 and FDA clearance in 2008 for the two component (2C) protocol. A self-contained, automated manufacturing system that processes blood components from whole blood units, the system consists of the Atreus device, the Atreus System Manager and disposable processing sets. The Atreus system’s informatics capabilities include Web-based communication, control and intelligence to allow blood centers to define workflow, detect deviations and monitor process performance. The OrbiSac device allows the processing of buffy coat platelets produced from the Atreus system into a single pooled platelet product ready for transfusion. The Orbisac system is not available for sale in the United States.
CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies. The company serves patients through its commitment to better blood and better lives by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit www.caridianbct.com.
Lisa Hayes, Vice President of Global Marketing and Corporate Communications
Phone: +1 303.231.4201